Healthcare Industry News: Xibrom
News Release - May 30, 2006
ISTA Pharmaceuticals Is Initiating Phase III Clinical Trials of a New Once-Daily Formulation of Xibrom(TM) for the Treatment of Ocular Pain and Inflammation Following Cataract SurgeryIRVINE, Calif., May 30 (HSMN NewsFeed) -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ) announced today that the Company is initiating two randomized, double-blind, placebo-controlled multi-center Phase III clinical trials of a new proprietary once-daily formulation of Xibrom(TM) (bromfenac ophthalmic solution) for the treatment of pain and inflammation following cataract surgery. Twice-daily Xibrom(TM) has been approved by the U.S. Food and Drug Administration for the treatment of ocular inflammation and reduction of ocular pain following cataract surgery.
"These Phase III studies of a once-daily formulation are a natural extension of ISTA's continued research with Xibrom," stated Vicente Anido, Jr., Ph.D., President and Chief Executive Officer of ISTA Pharmaceuticals. "The trials we are now initiating are designed to demonstrate that once-daily application of our new proprietary formulation of Xibrom can further reduce the number of daily doses, potentially improving compliance while maintaining effectiveness."
ABOUT Xibrom(TM) AND THE U.S. OPHTHALMIC ANTI-INFLAMMATORY MARKET
Xibrom(TM) (bromfenac ophthalmic solution) 0.09% is a sterile, topical, non-steroidal anti-inflammatory solution for the treatment of ocular inflammation and pain following cataract surgery. Senju Pharmaceuticals Co. Ltd. has marketed the twice-daily formulation of this product in Japan since 2000 with over 7.9 million uses since that time. ISTA acquired U.S. marketing rights for Xibrom(TM) in May 2002 under a license from Senju.
ISTA has completed two pivotal Phase III clinical studies of the twice- daily formulation of Xibrom(TM) in the United States. In these studies involving 527 patients, a statistically significant proportion of patients treated with Xibrom(TM) achieved treatment success, defined as the complete absence of ocular inflammation compared to those patients who received placebo. This effect was evident in the Xibrom(TM) group as early as day 3 following initiation of treatment. Furthermore, 75% of patients were pain-free within two days of being treated with Xibrom(TM) twice daily. In addition, 93% of patients receiving Xibrom(TM) twice daily were pain-free within six days of treatment.
The topical ophthalmic anti-inflammatory market consists of steroids, NSAIDs and combination products. Based upon 2005 prescription data from IMS, ISTA estimates that U.S. sales in 2005 in this market were approximately $400 million, with total prescriptions of 8.8 million.
For additional information on Xibrom(TM), including full prescribing information, please visit http://www.istavision.com/products/products_Xibrom.asp.
ISTA is a specialty pharmaceutical company focused on the development and commercialization of unique and uniquely improved ophthalmic products. ISTA's products and product candidates seek to address serious diseases and conditions of the eye such as dry eye, vitreous hemorrhage, diabetic retinopathy, hyphema, glaucoma, ocular pain and inflammation. Building on this pipeline, ISTA's goal is to continue its growth as a specialty pharmaceutical company through a combination of its own product development efforts and by acquiring complementary products and product candidates. For additional information regarding ISTA, please visit ISTA Pharmaceuticals' Website at http://www.istavision.com.
Any statements contained in this press release that refer to future events or other non-historical matters are forward-looking statements. For example, and without limiting the foregoing, the statements that ISTA will conclude its Phase III study of the once daily formulation of Xibrom(TM) in the fourth quarter of 2006, that ISTA will have the results of the Phase III study available by early 2007, and that ISTA will file a supplemental NDA for the once-daily formulation of Xibrom(TM) in 2007 are forward-looking statements. ISTA disclaims any intent or obligation to update any forward-looking statements. Such statements are based on ISTA's expectations as of the date of this press release and are subject to risks and uncertainties that could cause actual results to differ materially. Important factors that could cause actual results to differ from current expectations include, among others, risks, delays and uncertainties related to ISTA's Xibrom development program (including but not limited to the difficulty of predicting the timing or outcome of the Phase III study of the once-daily formulation of Xibrom and whether the results, if any, of such study will be adequate to support and file an NDA for such formulation); and such other risks and uncertainties as detailed from time to time in ISTA's public filings with the U.S. Securities and Exchange Commission, including but not limited to ISTA's Annual Report on Form 10-K for the year ended December 31, 2005 and its Quarterly Report on Form 10-Q for the period ended March 31, 2006.
Source: ISTA Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.